<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03891277</url>
  </required_header>
  <id_info>
    <org_study_id>2018YFC1312303</org_study_id>
    <nct_id>NCT03891277</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ferrous Iron on the Prevention of Vascular Cognitive Impairment Among Patients With Cerebral Infarction/TIA (FAVORITE)</brief_title>
  <acronym>FAVORITE</acronym>
  <official_title>Efficacy and Safety of Ferrous Iron on the Prevention of Vascular Cognitive Impairment Among Patients With Cerebral Infarction/TIA,FAVORITE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of Vascular Cognitive Impairment(VCI) is high in patients after ischemic
      stroke or transient ischemic attack(TIA) . Effective therapy for the prevention of VCI
      remains limited. The primary purpose of this study is to evaluate the efficacy and safety of
      Ferrous iron versus placebo on the prevention of vascular cognitive impairment among patients
      with ischemic stroke/TIA complicated with Hemoglobin deficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of Vascular Cognitive Impairment(VCI) remains 21%~70% among patients after
      ischemic stroke or TIA. Effective therapy for the prevention of VCI remains limited. Abnormal
      iron distribution and Systemic iron deficiency may contribute partly to the occurrence of
      VCI.The primary purpose of this study is to evaluate the efficacy and safety of Ferrous iron
      versus placebo in reducing the risk of VCI at 1 year in patients with cerebral Infarction/TIA
      complicated with Hemoglobin deficiency. The secondary purpose is to evaluate the effect of
      Ferrous iron on the Biological markers of VCI; to evaluate the effect of iron supplement on
      the outcome(death,stroke recurrence, dependency) of patients with ischemic stroke or TIA
      complicated with Hemoglobin deficiency at 3 months/1 year after treatment.

      This trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial.
      1006 patients in 20 centers in China will be enrolled with one of the following situations
      1.recent ischemic stroke or TIA (within 3 months) with Fe deficiency （serum
      ferritin&lt;20µg/L）or Hemoglobin deficiency(&lt;120g/L for female and &lt;130g/L for male).2. Vascular
      risk factors(hypertension, diabetes mellitus, or dyslipidemia), with multiply lacunar
      infarctions(≥2) or extensive white matter lesions（Fazekas ≥2） or multiply
      microhaemorrhage(≥2) showed on CT/Magnetic Resonance(MR) with Fe deficiency （serum
      ferritin&lt;20µg/L）or Hemoglobin deficiency(&lt;120g/L for female and &lt;130g/L for male).. Patients
      will be randomly assigned into 2 groups according to the ratio of 1:1:

      Ferrous iron therapy (0.2 per day) Placebo Face to face interviews will be made at baseline,
      14 (or hospital discharge), 3th month± 7 days and 12th month ± 14 days after randomization.

      Primary outcome is defined as prevalence of Vascular Cognition Impairment at 1 year after
      treatment. Secondary outcomes include all-cause death; ischemic stroke; transient ischemic
      attack; poor functional outcome (mRS 2-6). Safety outcomes, relating to adverse
      gastrointestinal reactions and iron overload.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Two nearly identical tablet forms of Ferrous iron (0.2g Ferrous iron and matching placebo) with almost the same size, color and smell will be used in this research.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>prevalence of vascular cognitive impairment in patients given Ferrous succinate versus placebo</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Vascular cognitive impairment will be diagnosed with Montreal Cognitive Assessment(MoCA, range 0-30 scores) &lt;26 scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>All-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke recurrence (including hemorrhagic and ischemic stroke)</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>Stroke recurrence including hemorrhagic and ischemic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Poor functional outcome</measure>
    <time_frame>1 year after randomization</time_frame>
    <description>The modified Rankin Scale (mRS range 0-6)= 2-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of Hemoglobin/serum ferritin/serum Tau/serum Aß</measure>
    <time_frame>3 months and 1 year after randomization</time_frame>
    <description>Value of Hemoglobin/serum ferritin/serum Tau/serum Aß</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1006</enrollment>
  <condition>Vascular Cognitive Impairment</condition>
  <condition>Dementia, Vascular</condition>
  <condition>Iron-deficiency</condition>
  <condition>Cerebral Infarction</condition>
  <condition>TIA</condition>
  <arm_group>
    <arm_group_label>Ferrous succinate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ferrous succinate sustained-release tablets（Ferrous succinate 0.2g）1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo with almost the same size, color and smell as Ferrous iron will be used with 1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous succinate</intervention_name>
    <description>Ferrous succinate sustained-release tablets（Ferrous succinate 0.2g）1 tablet, Qd,po during or after breakfast, Lasting for 12 weeks.
placebo with almost the same size, color and smell as Ferrous iron will be used with 1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks.</description>
    <arm_group_label>Ferrous succinate</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age :18-80 years old , male or female;

          2. one of the following situations: A.recent ischemic stroke or TIA (within 3 months) B.
             One or more vascular risk factors including hypertension, diabetes mellitus, or
             dyslipidemia, with multiply lacunar infarctions(≥2) or extensive white matter
             lesions（Fazekas ≥2） or multiply microhaemorrhage(≥2) showed on CT/MR.

          3. Fe deficiency （serum ferritin&lt;20µg/L）or Hemoglobin deficiency(≥60 g/L and &lt;120g/L for
             female,or ≥60 g/L and &lt;130g/L for male)

          4. Signed informed consent.

        Exclusion Criteria:

          1. CT/MR showed Intracranial haemorrhage or non-cerebral vascular disease (eg.
             intracranial tumors, multiple sclerosis);

          2. Patients who Can not cooperate with the completion of neuropsychological evaluation
             for Severe hearing impairment, visual impairment, unilateral neglect, or dyskinesia;

          3. Patients with Severe anemia with Hemoglobin&lt;60 g/L;

          4. Patients with thalassemia, megaloblastic anemia or erythronoclastic anemia.

          5. Patients with Mental illness or schizophrenia;

          6. Patients who were diagnosed definitely as Alzheimer's disease;

          7. Patients having history of taking drugs including Cholinesterase inhibitors、NMDA
             antagonists、5-hydroxytryptophan receptor antagonists、pyrrolidone and other definite
             drugs for improving cognition(e.g. donepezil、Galanthamine、Memantine、huperzine
             A、oxiracetam、aniracetam、piracetam、butyphthalide) within 3 months before randomization；

          8. Patients with severe liver or kidney insufficiency(ALT&gt;twofold upper normal limit or
             Aspartate Aminotransferase&gt;twofold upper normal limit; Cr&gt;1.5 times upper normal limit
             or Glomerular Filtration Rate&lt;40 ml/min/1.73m2）;

          9. Patients with Severe untreated urinary tract infection;

         10. Patients with hemochromatosis or hemosiderosis(e.g. Iron lung deposition);

         11. Patients with Iron allergy or other contraindications of using Iron；

         12. Pregnant or childbearing-age women；

         13. Patients who are undergoing experimental drugs or device tests;

         14. Patients Unable to finish the follow-up of 3 months or 1 year due to geographical
             factor or other reasons;

         15. Patients or legal representatives refuse to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia Qian, doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhang shuting, doctor</last_name>
    <role>Study Director</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jia Qian, doctor</last_name>
    <phone>15810048909</phone>
    <email>jiaqian1616@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jia weili, doctor</last_name>
    <phone>13120207987</phone>
    <email>13120207987@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing tiantan hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia Qian, doctor</last_name>
      <phone>15810048909</phone>
      <email>jiaqian1616@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jia Weili, master</last_name>
      <phone>13120207987</phone>
      <email>13120207987@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Yongjun Wang</investigator_full_name>
    <investigator_title>86(010)59978351</investigator_title>
  </responsible_party>
  <keyword>Vascular Cognitive Impairment</keyword>
  <keyword>dementia</keyword>
  <keyword>iron deficiency</keyword>
  <keyword>cerebral infarction</keyword>
  <keyword>TIA</keyword>
  <keyword>biological markers</keyword>
  <keyword>Clinical Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferrous succinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

